Board Changes, Business Update & Notice of Results

Futura Medical plc (AIM: FUM), is pleased to announce that, further to the Board Changes announced on 8 July 2025, Alex Duggan has been appointed to the Board of Directors as interim Chief Executive Officer. This follows the completion of all required due diligence and regulatory checks. Alex brings over 25 years of leadership experience in the Consumer Healthcare and Prescription (Rx) sectors. He has a proven track record of driving business transformation through M&A, operations and organic growth across global markets.

The Group also announces that Angela Hildreth has notified the Board of her intention to step down as Finance Director and Chief Operating Officer. Angela will remain in her role and as a Director of the Company during her six-month notice period, continuing to support the Group and overseeing an orderly handover of responsibilities once a successor has been appointed. The Board would like to thank Angela for her significant contribution and commitment to the business throughout her tenure.

Business Update

As a new product in a new category, Eroxon sales performance remains unpredictable and sales trends (including the impact of previous channel fill) remain challenging to identify and predict. The momentum of sales of Eroxon continues to be slower than originally anticipated, with varying degrees of traction across different territories.

Reflecting on this slower momentum, alongside the challenges and learnings from Eroxon's initial product launches, the Board, led by Alex Duggan, is conducting a thorough review of the current business and its commercial plans. This includes, but is not limited to, the Company's sales and marketing strategies for Eroxon as well as the costs associated with the business and other possible strategic options available to the Group.

The Board anticipates that it will be able to provide an initial update on its review of the business and strategy at the time of its interim results, which are currently expected to be published in late September.

Andrew Unitt, Senior Independent Director, commented:

"We are pleased to formally welcome Alex to the Board. His experience and decisive leadership will undoubtably prove instrumental at this phase of the Group's development.

We are grateful to Angela for her many years of dedicated service to the Company, during which she oversaw a period of significant development. We wish her all the best in her next chapter."

Alex Duggan, CEO of Futura, commented:

"I am pleased to join the Board and to step into the interim CEO role at this pivotal juncture for the Group. I will be working closely with the Board and the wider team in my review of the business, its priorities, and its strategic options over the period ahead. Our priority is to deliver a clear strategy that will maximise value for shareholders, commercial partners and employees."

In accordance with Schedule 2 paragraph (g) of the AIM Rules for Companies, Alexander James Hanbury Duggan (aged 54 years) holds/has held the following directorships/partnerships in the last five years:

Opus Healthcare Limited

Alliance Pharma (Ireland) Limited

Alliance Pharmaceuticals SAS

Alliance Pharma France SAS

Alliance Pharmaceuticals GMBH

Alliance Pharma Srl

Alliance Pharmaceuticals Spain SL

Advanced Bio-Technologies, Inc

Alliance Pharma Inc

Alliance Pharmaceuticals (Asia) Ltd

Synthasia International Company Ltd

Alliance Pharma (Singapore) Pte Ltd

Alliance Pharmaceuticals (Thailand) Co., Ltd

Alliance Pharmaceuticals (Philippines) Corp

Alliance CHC (India) Pte Ltd

Alexander Duggan was a Director of The Paradigm Organisation Ltd, appointed on 26 June 1996. Following a court order to wind up the business on 21 October 1997, Alexander Duggan resigned as a Director on 24 October 1997 and the Company dissolved on 10 April 2000.

There are no further disclosures to be made pursuant to Schedule 2 paragraph (g) of the AIM Rules for Companies.

596/2014 as amended by the Market Abuse (Amendment) (EU Exit) Regulations 2019.